In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, gaining as much as 25% earlier in the day. The move up comes as the S&P ...

When considering tomorrow's earnings volatility, it's worth noting that analysts are mostly bullish on Teva Pharmaceuticals stock. Of the eight brokerages in coverage, seven carry a "strong buy ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Alvotech’s commercial partners include Teva Pharmaceuticals ... the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price ...